BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 13, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 16, 2019
View Archived Issues
Using promiscuity to identify high-commitment targets
Read More
Local vaccine can induce global remission
Read More
Design of EBNA1-specific inhibitors suppressing Epstein-Barr virus-driven tumor growth
Read More
CCR1 is differentially expressed across ovarian cancer subtypes
Read More
Phase II dose of cancer vaccine IMU-131 identified in HER2/neu-overexpressing stomach cancer trial
Read More
Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint
Read More
Alnylam initiates global phase III pediatric ILLUMINATE-B study
Read More
Clinical program update on ADVM-022 gene therapy
Read More
Synapse formation important for ketamine durability
Read More
Preclinical characterization of PF-06882961
Read More
S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease
Read More
RTI-1092663 improves metabolic syndrome in mice
Read More
Shenyang Pharmaceutical University patents neuraminidase inhibitors
Read More
Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS
Read More
FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease
Read More
Diamyd Medical presents 30-month results from phase IIa EDCR study
Read More
MediciNova moves forward with a phase III study of MN-166 in ALS
Read More
CStone Pharmaceuticals announces dosing of first patient in phase III GEMSTONE-303 study
Read More
Positive interim results presented from phase I study of CERC-301
Read More
Positive 12-month data presented from phase II study of Clascoterone
Read More
Interim results presented from phase II study of chikungunya virus vaccine candidate
Read More
Cortexyme launches phase II/III study of COR-388 in subjects with Alzheimer's disease
Read More
